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CAPD with an amino acid dialysis solution: A long-term, cross-over
study. This prospective cross-over study was undertaken to evaluate
the safety and efficacy of a 1% amino acid dialysis solution on the
nutritional and metabolic changes, plasma amino acid profiles and
peritoneal membrane function of patients on CAPD. Six CAPD patients
had one exchange a day with two liters of this solution over a six month
period. Every month there was a medical examination, anthropometric
measurements and dietary inquiry were made, blood biochemistry tests
were done. Every three months renal function, peritoneal function,
aminograms of plasma and dialysate and nitrogen balance were deter-
mined. Data were compared with those obtained one month prior to and
three months after withdrawal of amino acid administration. Nitrogen
balance, which was negative (—1.3 g/day) became positive (+3.1 g/day).
Patients who were already overweight increased in weight, both in fat
and lean mass. Plasma cholesterol and triglycerides significantly de-
creased and the amino acid profile moved towards normal; plasma urea
levels increased and pH and bicarbonate decreased slightly but signif-
icantly (P < 0.05). Plasma protein concentrations did not change. All
the above parameters turned towards basal values when amino acids
were discontinued. We conclude that amino acids can be used as
osmotic agents for CAPD since they do not cause toxic effects or impair
peritoneal membrane function. Moreover, they can help the nutritional
status, provided that an increase in weight is prevented and the slight
worsening of systemic acidosis is corrected.
Uremic patients have been reported to have many abnormal-
ities of plasma and intracellular amino acid concentrations,
which are in part due to malnutrition and associated with a
negative nitrogen balance, and in part also seen in well nour-
ished uremic patients, more strictly related to the metabolic
disturbances of uremia [1—3]. Neither hemodialysis nor perito-
neal dialysis (PD) correct these derangements [4—7]. Instead
loss in the dialysate can worsen these abnormalities in PD
patients [8, 9].
Dc Ferrari et a! [10] have demonstrated that plasma amino
acid concentrations can affect brain cell uptake; it follows that
uremic encephalopathy and perhaps other metabolic distur-
bances could be related to plasma amino acid abnormalities,
although plasma concentrations do not always reflect intracel-
lular concentrations [3]. Orally or intravenously administered
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amino acid or ketoanalogs can produce a positive nitrogen
balance in uremic patients, but intra- and extracellular amino
acid concentrations appear to be more difficult to correct [11—
13]. An Other major problem in CAPD is development of both
hyperdyslipidemia and obesity, which have been ascribed to the
continuous absorption of glucose from the dialysate [14]. The-
oretically, most of these drawbacks of CAPD could be obviated
by partially or intermittently replacing glucose with amino acids
in the dialysis solutions.
The peritoneum is a physiological way to administer amino
acids, since the dialysis solutions encounter the liver before
entering the systemic circulation. In 1968 Gjessing [15] first
demonstrated that this system is feasible and safe. As shown
more recently by Oreopoulos et al in pilot studies [16, 17],
intraperitoneally administered amino acids are easily absorbed
into the blood, where they reach concentrations as high as those
after a protein meal and are well tolerated. The ultrafiltration
effect of a 1% amino acid solution was intermediate between
those of 1.5% and 2.5% glucose monohydrate solutions [17].
Finally, they are effective in removing nitrogen compounds.
The availability of industrially manufactured CAPD bags con-
taining amino acid solutions has made it possible to use them
widely in a clinical setting. However, so far we know of only
two studies that have been published [18, 19], and many aspects
of using amino acid solutions intraperitoneally are still largely
uninvestigated.
We report here the effects of an amino acid solution with a
composition similar to that we proposed in a previous study [7],
instead of the usual glucose solution, in one exchange a day,
over a six month period; included are data on nutritional status,
lipid pattern, acid-base balance, plasma amino acid profile and
other biochemical parameters, and on peritoneal membrane
function of six CAPD patients.
Methods
Six patients (4 males and 2 females), aged 63.2 6.5 SDyears
(range 52 to 72 years), on CAPD for at least three months (15.7
16.2 months, range 3 to 45 months) were studied. Three out
of them had a residual renal function (creatinine clearance 6 to
8 mI/mm), while three were anuric. Two patients had diabetic
nephropathy, one polycystic kidney disease, two chronic pyelo-
nephritis and one arteriolar nephrosclerosis. Informed consent
was obtained from all patients. The protocol excluded patients
who had more than one episode of peritonitis in the six months
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I—Amino acids
pinol/liter A B
H—Electrolytes (mmol/liter): sodium 129, calcium 1.75, magnesium
0,75, chloride 108, lactate 35, pH 6.1, osmolality (mOsm/liter) 332
A, from manufacturer's formulation; B, from our analyses of five
bags (Means SD).
before or one episode of peritonitis in the month prior to the
beginning of the study. Only one patient was hospitalized for a
short period during the study; that was because of an exit site
infection which required catheter replacement. During the
treatment, two patients complained of one peritonitis episode
each and one patient complained of two episodes, but they did
not discontinue the trial.
The 1% amino acid solution was provided by Baxter-Tra-
venol, R&D Europe: two liters of solution were contained in a
three-liter plastic bag with aluminum foil overpouch, with
nitrogen between the bag and overpouch. The solution is ready
to use, can be warmed to body temperature prior to the infusion
in the peritoneal cavity and has a shelf life of 12 months. Its
composition is listed in Table I; both the manufacturer's
formulation and our own analyses of the amino acids are
shown. All the patients were using two-liter glucose solution
(Dianeal) three (1 patient) or four (5 patients) times a day, seven
days a week. One bag of the amino acid solution was substi-
tuted just before lunch for the usual 1.36% or 2.27% glucose
solution.
Medical examinations were given once a month, anthropo-
metric measurements and a dietary inquiry made, and blood
biochemistry tests also done monthly while on the amino acid
infusion. Renal function, peritoneal function, aminograms of
plasma and dialysate, and an estimate of nitrogen balance were
checked quarterly. Basal values were two separate sets of
determinations obtained over one month prior to amino acid
administration. All the above parameters were re-examined
three months after amino acid administration was discontinued.
Anthropometric measurements included height, weight after
draining, triceps, biceps, subscapular and suprailiac skin-fold
thickness, and midarm muscle circumference. The percentages
of fat content with respect to the body weight and of the body
weight with respect to ideal body weight were calculated.
Estimates of protein and caloric intake were based on three-
day dietary records. Venous blood samples for biochemical
determinations were taken in the morning in the fasting state,
after a 1.36% glucose overnight exchange. Arterial blood sam-
ples in the same occasion were drawn for gas analysis. Proteins
Table 2. Anthropometric measurements and blood pressure
Before
During After 3rd
month3rd month 6th month
Body wt kg
%IBW
Fat%BW
MAMCmm
Skin fold surn"mm
Blood pressure
Systolic mm Hg
DiastolicmmHg
73.7 9.3
120±17
33±8.6
23±4
79 39
143 32
80±12
75.8 8.5 78 9.6"
124±16 127± l7
34±9 35±10
23±4 24÷4b
85 41 90 41
142 29 138 33
83±15 80±7
78.4 8.9"
127± l5
35±10"
244b
91 46
140 29
83±14
were determined by immunonephelometry and amino acids by
the LKB alpha 4150 aminoanalyser, after deproteinization with
sulphosalicylic acid. Twelve healthy subjects (6 males and 6
females, mean age 63 6 years) served as controls for plasma
amino acids. Residual renal function was the mean of urea and
creatinine clearances. Peritoneal function was assessed after a
1.36% glucose overnight exchange, with a bag containing 3.86%
glucose solution, left in place for four hours. The volume of
dialysate drained was considered to be a measure of the
peritoneal ultrafiltration capacity. During the same time, blood
and dialysate samples were obtained after two and four hours
for urea and creatinine measurements. Equilibration curves
were then calculated for dialysate-to-plasma urea or -creatinine
concentrations versus time.
Nitrogen balance was calculated from dietary intake, perito-
neal aminoacid load, urinary losses (calculated as the sum of
protein, urea, creatinine, uric acid) and dialysate losses (as
above plus amino acids). Nitrogen losses in feces and sweat
were estimated as a fixed amount of 1.6 g a day 20J.
The paired and unpaired Wilcoxon rank sum tests were used
for statistical analysis.
Abbreviations for amino acids conform to the rules of
IUPAC-IUB Commission on Biochemical Nomenclature [21].
Results
Nutritional status
Nutritional status was assessed from anthropometric mea-
surements, dietary inquiry, nitrogen balance and serum protein
concentrations. The anthropometric measurements are listed in
Tahle 2. All the patients were overweight at the beginning of the
study and all but one further increased in weight, both in fat and
lean mass. Consequently, mean body weight increased signifi-
cantly (P <0.05). Dietary calorie intakes (Table 3) increased by
26% and protein by 16% and patients agreed that their appetites
had increased. Glucose peritoneal load decreased by 40 g a day,
on the average.
Table 3 also shows nitrogen balance data. There was a
significant change from negative to positive mean values (P <
0.05), and by the sixth month nitrogen balance had become
positive in all the patients. This shift was mainly due to the
absorption of the peritoneally administered amino acids, as
indicated by the amino acid nitrogen balance, which accounted
Table 1. Composition of the investigated solution
Threonine
Serine
Proline
Glycine
Alanine
Valine
Methionine
Isoleucine
Leucine
Tyrosine
Phenylalanine
Lysine
Histidine
Arginine
4860
4340
4640
6080
9560
10660
5100
5800
6900
330
4500
4670
4120
5500
5005 864
4430 670
4860 676
6302 766
9820 1308
11060 1767
5407 805
6192 938
7092 899
372 67
4593 663
4773 740
4158 512
5735 291
Abbreviations are: Body wt, body weight; IBW, ideal body weight,
MAMC, middle arm muscle circumference.
a Sum of biceps, triceps, subscapular and suprailiac skin fold thick-
ness. All data are means SD.
"P C 0.05 vs. before.
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Table 3. Nutrient intakes, nitrogen balances and peritoneal losses
Before
During After 3rd
month3rd month 6th month
Dietary calories 23 3 28 5" 29 5" 27 4
kcallkg IBW
Dietary proteins I 0.2 1.14 0.11 1.16 0.10 1.16 0.17
glkg IBW
Peritoneal 177 88 131 6 134 62" 175 56"
glucose load
glday
Peritoneal 2978 243 2821 286 2875 333 2971 226"
osmotic load
mOsmlday
Daily ultrafiltrate 1074 440 888 327" 930 402 994 298b
ml
Overal nitrogen —1.3 1.8 2 1.3" 3.1 1.3" —0.6
balance glday
Peritoneal amino —0.4 0.1 1.8 0.2 1.7 0.1" —0.3 01b
acid N balance
giday
Peritoneal protein 1.4 0.4 1.6 0.6 1.4 0.4 1.4 0.4
N losses glday
Peritoneal urea N 6.3 0.9 6.1 1.1 6.1 1 5.6 0.9
losses glday
All data are means so.
a P < 0.05 vs. before
b P < 0.05 vs. 6th month
for more than 2 g of the overall nitrogen balance. On the other
hand, losses of protein and urea nitrogen in the dialyzate did not
change during the study.
The ultrafiltration rates associated with the amino acid ex-
changes varied from 178 to —35 ml (mean 36 84 ml).
A slight decrease in osmotic load (including that of the amino
acid solution) and a parallel decrease in the overall ultrafiltra-
tion would suggest that water retention might have contributed
to some extent to the increase in body weight. However, water
retention, if any, was not detectable in any of the patients nor
was it suggested by decreases in serum protein or plasma
hemoglobin values, nor by increases in blood pressures. Instead
serum protein concentrations (Table 4) and blood pressure did
not change.
Biochemical parameters
The most remarkable biochemical changes were in plasma
urea, which increased from 140 to 180 mgldl in the second
month (P < 0.05) and slowly decreased thereafter to 160 mg/dl
in the sixth month (Fig. 1). Alkaline phosphatase decreased
significantly (P < 0.05), while decreases in calcium and PTH
were slight and not significant. Total cholesterol, RDL-choles-
terol and triglycerides decreased; LDL and VLDL did not
change (Table 4).
Arterial blood pH and plasma bicarbonate concentration fell
slightly, but remained quite close to normal. Chloride replaced
the lost bicarbonate in the anion column and consequently the
anion gap did not change significantly.
All the above changes, save the alkaline phosphatase, disap-
peared after amino acid withdrawal.
-
Table 4. Blood biochemistry
During After 3rd
Before 3rd month 6th month month
Urea mgldl 138 20 168 33" 157 31 139 25"
Creatinine mg/c/I 8.6 2.1 9.1 1.3 8.9 1.7 9 2.1
Uric acid mgldl 6.6 1.3 6.0 1.3 6.8 1.3 6.7 0.9
Na mmollliter 139 2 140 2 139 2 142 2
K mmollliier 4.2 0.7 4.7 0.5 4.4 0.7 4.7 0.6
Cl mmollliter 97 4 99 3 102 5 100 4
Ca ing/dI 9.8 1 9.1 0.7 9 0.8 9.7 0.9
Mg mgldl 2.9 0.2 3.1 0.3" 3 0.2 3.2 0.1
P mg/c/I 4.6 0.8 4.9 0.7 4.7 1 4.7 0.6
Alk. Phos. 145 43 112 4Ø 112 39" 116 48"
mU/mI
iPTH pg/,nl 274 166 — 210 139 245 135
Cholesterol 253 40 235 41 227 26 240 32"
mgldl
Triglycerides 276 130 213 82" 214 88 296 107"
mgldl
HDL-cholesterol 38 10 35 14 31 6" 29 io"
mgldl
LDL mg/dl 166 51 141 66 140 45 152 47
VLDL mg/c/I 39 12 43 17 44 20 41 17
pH 7.39 0.05 7.34 0.04" 7.34 0.03" 7.38 0.02"
Bicarbonate 23 3 19 2 20 2 22
mmollliter
Anion gap 19 6 22 3 19 3 19 3
mmollliter
Hemoglobin 10.3 3 9.8 2.3 10.4 2.3 10.2 2
g/dl
Hematocrit % 31 9 30 8 31 7 30 6
Total protein 7.1 0.3 7.0 0.4 7.1 0.3 7.0 0.7
g/dl
Albumin g/dl 4.0 0.4 3.9 0.3 3.9 0.3 3.9 0.3
Transferrin 263 61 233 33 244 31 252 60
mg/dl
All data are means SD.
"P < 0.05 vs. before
b P < 0.05 vs. 6th month
Table 5. Peritoneal function
During
Before 3rd month 6th month
Net ultrafiltration 846 262 1010 241 918 160
capacity mlI4 hrs
Peritoneal clearances
Urea mI/mi,, 6.5 1.2 5.6 0.3 5.6 0.3
Creatinine mi/mm 5.3 1 5.0 0.6 4.7 0.6
Peritoneal permeability
DIP urea 2 hr 0.76 0.08 0.80 0.07 0.73 0.06
D/P urea 4 hr 0.94 0.01 0.89 0.07 0.89 0.06
DIP creatinine 2 hr 0.60 0.06 0.64 0.06 0.56 0.05
DIP creatinine 4 hr 0.75 0.04 0.79 0.09 0.78 0.11
All data are means SD. D/P = dialysate-to-plasma ratio.
Peritoneal membrane function
Neither ultrafiltration capacity nor clearance or permeability
to urea or creatinine varied significantly while on treatment
(Table 5),
Plasma amino acid profile
Basal mean plasma amino acid levels of the six patients
(Table 6) differed from those of the control group for PSE,
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Table 6. Plasma amino acid concentrations (smol/liter)
Norma!
(No. 12)
Patient (No. 6)
Before
During After 3rd
month3rd month 6th month
PSE 33 10 18 9 27 15 33 iib 36 17b
TAU 53 14 57 39 75 36 62 23 96 54
THR 123 27 91 22 124 33 138 25b 95 15C
SER 95 21 67 15 86 16b 98 15b 109 37
ASN 43 8 45 27 64 28 63 24 74 40b
GLU 34 28 42 34 50 33 43 40 69 37
GLN 441 75 491 135 537 135 644 65" 515 240
PRO 271 72 310 110 347 135 430 110b 424 200b
GLY 215 51 196 42 185 46 228 44 259 61
ALA 341 70 325 102 322 103 387 93 400 45
CIT 32 12 104 4I 127 44 215 46b 100 49C
VAL 217 43 182 50 220 66 233 98 172 36
CYS 79 22 86 47 82 36 84 27 107 65
MET 31±8 26±9 45±29" 35±10 37±31
ILE 88 23 59 28 77 39 62 21 49 30
LEU 125 25 101 29 132 40" 131 46b 98 30
TYR 70 18 36 8' 55 17 51 12 38 5
PilE 53 9 65 25 94 65 98 68" 72 38
ORN 101 32 86 29 96 20 105 20b 91 29
LYS 171 34 158 47 167 37 171 31 151 35
1MH 8 16 76 40' 70 50 45 32b 77 66
HIS 64 14 64 18 78 23 83 26 73 25
3MH 0±0 43±8' 44±29 43±32 40±27
ARG 45 19 63 II' 74 18 81 21" 60 29
TOT 2754 309 2808 510 3177 416 3564 346b 3262 546
EA 821 117 693 121 859 181b 867 156b 673 132C
NEA 1933 243 1972 414 2178 348 2574 ,47b 2359 236
TYR/PHE 1.32 0.21 0.64 0.2W' 0.74 0.43 0.61 0.20 0.61 0.23
VAL/GLY 1.06 0.32 0.93 0.20 1.33 0.81 1.05 0.49 0.62 0.28c
a P < 0.05 vs. normal values
b p < 0.05 vs. basal values
P < 0.05 vs. 6th month values
acids, total non-essential amino acids (NEA), total essential
amino acids (EA), PSE, THR, SER, GLN, PRO, CIT. LEU,
PHE, ORN, ARG.
There was a significant decrease only in 1MH, while the other
amino acids remained unchanged. Concentrations of all the
amino acids administered in the solution increased in plasma,
but so did there of some amino acids not present in the solution,
such as ASN, GLN, CIT and ORN. After amino acid with-
drawal THR, CIT, EA, VAL/GLY ratio significantly de-
creased; only PSE, ASN and PRO remained higher than before
amino acid administration.
Discussion
The long-term use of glucose as the osmotic agent for CAPD
is known to have some important drawbacks, essentially related
to the fact that a significant amount of it is absorbed through the
______
peritoneal membrane. On the other hand, we still do not have
an ideal substitute, and none of the substances so far proposed
is without most of the disadvantages described for glucose.
Amino acids are potential substitutes for glucose in the
dialysate, and might even be better because of the remarkable
abnormalities of the amino acid pool in uremic patients. How-
ever, routine use has, so far, been delayed by difficulties in
industrial manufacturing and by unsatisfactory long-term sta-
bility of the amino acid solutions.
The recent production by Baxter-Travenol of an amino acid
18O
E 160-
140-
f
0 4
Time, months
Fig. 1. Changes in plasma urea levels during treatment with a,nino
acids. All data are means SEM, Symbols are: (• •) amino acid
CAPD; (O—O) usual CAPD. * P< 0.05 vs. basal values; ** P < 0.05
vs. last month on amino acids.
THR, SER, ILE, TYR concentrations and TYRJPHE ratio,
which were decreased, and for CIT. ARG, 1MH, 3MH, which
were increased. This agrees with previous reports from other
authors [6, 8] and ourselves [7]. After six months of treatment,
the following parameters were increased (P < 0.05): total amino
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solution which meets most of our requirements for composi-
tion, stability and ease of use prompted us to design the present
study of the effects of the long-term use of amino acid solutions
for dialysis. Since the complete substitution of amino acid
solutions for glucose solutions could be expected to cause sharp
increases in plasma nitrogen compounds, we decided to use a
single daily exchange with amino acid solutions.
In good agreement with other groups [16], we also found that
amino acid-containing dialysate is well tolerated by patients on
CAPD; the scheduled one exchange a day of two liters of a 1%
amino acid solution did not induce toxic effects nor impair
peritoneal membrane function. The most important effect on
nutritional status was a positive nitrogen balance even after
correction for the increase in urea pool; nitrogen balance
reverted to negative values when patients were crossed-over to
usual CAPD. We also observed a statistically significant in-
crease in body weight as well as in lean body mass, estimated
by the middle arm muscle circumference, that persisted for
three months after amino acid withdrawal.
The further increase in weight of patients who were already
overweight was not good, of course. Some of the above
increases in weight might have been due to subclinical water
retention, and indeed patients on CAPD with amino acids
showed lower ultrafiltration volume along with normal ultrafil-
tration capacity, because of a reduced osmotic load. However,
since neither serum protein concentration nor hematocrit
changed during amino acid infusion, water retention, if any,
must have been negligible. Therefore we conclude that there
was a true increase in body weight, related to a significant
increase in caloric intake as was also documented by dietary
records. It is likely that a general improvement in well being led
to an over-consumption of calories during amino acid dialysis.
No further changes in body weight and composition occurred
when amino acids were discontinued. The increase in body
weight may reflect a propensity to gain weight by these patients,
that amino acids may have elicited or enhanced, and suggests
the advisability of more careful control of the caloric supplies of
patients on amino acid CAPD.
Our results for serum proteins agree with those of Pedersen et
al [18], with no changes in albumin or transferrin levels. Young
et al [19] found significant increments in serum transferrin, and
perhaps we did not because the basal serum protein profiles of
our patients were normal.
The increased urea levels are the consequence of the in-
creased nitrogen load. However, as shown in Figure 1, mean
plasma urea peaked in the second month of treatment, and then
decreased slowly. The final slight increase in urea was unlikely
to imply significant adverse effects in terms of the patients' well
being.
The meaning of the lipid changes observed is more intriguing,
since the reduction of cholesterol and triglycerides was coun-
teracted by a parallel decrease in HDL-cholesterol and there
were no changes in lipoproteins. However, changes in choles-
terol and tryglicerides are likely to be linked to amino acid
administration, since they significantly increase after reversion
to usual CAPD.
Reductions of blood pH and bicarbonate have been observed
and these could represent potential risk of impairment of the
uremic bone disease. This increase in fixed acid production, to
be ascribed to both amino acid load and to the presence of
lysine in the hydrochloric form, could be obviated by increasing
alkali supply.
Long-term peritoneal infusion with amino acids induced
remarkable and complex changes in the plasma amino acid
profile, with all EA, except ILE, increasing in concentration
toward the normal range. On the other hand, some NEA that
were normal basally increased above the normal range, and
others which were already high increased further. Whether
these changes in amino acid profile are meaningful metaboli-
cally or clinically is not clear at present. However a plasma
amino acid pattern closer to that of healthy controls, as is
obtained by long-term amino acid treatment, should genuinely
indicate a general improvement of the nutritional status of the
patients on CAPD.
The overall results of the present study allow us to conclude
that amino acids can be safely used as osmotic agents in CAPD.
In the long-term follow-up of our uremic patients no serious
adverse effects could be ascribed to amino acid infusion, given
as herein proposed. On the other hand, such changes as the
reversal of nitrogen balance towards positive values and the
improvement of some biochemical and nutritional parameters
are obviously advantages of the amino acid dialysate.
We still must determine whether longer term use, at higher
daily doses of amino acids, will provide more benefits and be
without adverse effects than those obtained in this study. The
results of our study clearly encourage further trials to establish
the proper dosage of amino acids and to better define if amino
acid solutions will be indicated for all CAPD patients or limited
to those with protein malnutrition.
Reprint requests to Dr. Michele Bruno, Divisione di Nefrologia e
Dialisi, Ospedale Mauriziano Umberto I, Largo Turati 62, 10128,
Torino, Italy.
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